Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of 7v-PCV on S. Pneumoniae Carriage in Jordanian Infants
NCT00900978Phase 2
Key facts
- Status
- Unknown
- Start
- May 2009
- Primary completion
- Aug 2010
- Countries
- 1
- Sponsor
- German-Jordanian University
- Modality
- Split/Subunit Vaccines
- Conditions
- pneumococcal infection
01
Overview
Phase 2, open-label, single-arm trial of pneumococcal 7-valent conjugate vaccine in pneumococcal infection, sponsored by German-Jordanian University. Primary endpoint: Decrease colonization with S. pneumoniae at 1.5 years. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
7v-PCV (Prevenar)
Infants receiving 7v-PCV at 3, 5, and 10 months of age.
03
Who it enrols
Healthy newborns in Ajlun city, Jordan, eligible for the national vaccination program.
04
Endpoints
Primary
Decrease colonization with S. pneumoniae
Secondary
Decrease infections related to S. pneumoniae
Antibiotic Resistance Patterns
Beyond the preview
Go deeper on NCT00900978.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00900978.